- +603-3310 0819
- [email protected]
Oncode connects clinical diagnostics, diagnostic technologies, bioinformatics, data intelligence, and translational research within one integrated ecosystem – transforming molecular insight into validated, deployable solutions for real-world healthcare.
Built on a decade of clinical implementation, our technologies and capabilities are designed to support healthcare providers, laboratories, researchers, pharmaceutical companies, and industry partners across borders.
Oncode’s technology ambitions are built on an operating clinical foundation, external quality validation, institutional backing, specialist capability, and growing regional presence.
Internationally recognised quality standards through Oncode’s clinical diagnostics arm.
Participation in CAP, EMQN, UK NEQAS, RCPA, and IQN Path external quality assessment and ring-trial programmes.
Supported by Malaysian Technology Development Corporation, a technology investment company wholly owned by Khazanah Nasional Berhad, Malaysia’s sovereign wealth fund.
The Oncode Innovation Centre was launched by Malaysia’s Ministry of Science, Technology and Innovation.
Specialist recognition reflecting internationally aligned capability in hematology precision medicine.
Presence and partnerships spanning Malaysia, Singapore, Indonesia, Hong Kong, Taiwan, and Thailand.
Oncode connects the capabilities required to move precision medicine innovation from scientific possibility into practical healthcare application.
Each capability creates value independently. Together, they form a connected system for discovery, validation, intelligence, implementation, and scale.
Clinical-grade molecular diagnostics supporting oncology, hematology, hereditary cancer, rare disease, and emerging applications.
Scientific, analytical, and clinical validation are built into every pathway.
Operating expertise becomes standardised assays, systems, and workflows.
Diagnostics, research, technology, and data remain connected from discovery to adoption.
Solutions and partnerships are developed for diverse Asian healthcare systems.
We work across healthcare, research, life sciences, government, and commercial partners.
Oncode is expanding its regional precision medicine presence through clinical services, diagnostic technology partnerships, research collaborations, and commercial relationships across Malaysia, Singapore, Indonesia, Hong Kong, Taiwan, and Thailand.
Oncode works with partners who want to move precision medicine from possibility to practical adoption.
Hospitals, specialist centres, clinicians, diagnostic laboratories, and healthcare networks.
Pharmaceutical companies, biotechnology companies, and diagnostic technology partners.
Universities, research institutions, investigators, and clinical study collaborators.
Distributors, market-access partners, investors, government agencies, and industry stakeholders.
We welcome collaborations in clinical diagnostics, diagnostic technology development, data and bioinformatics, translational research, regional market access, and strategic investment.
